TriSalus Life Sciences

TLSI

Market cap $286M

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Di.

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity.

TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 31, 2025, and provides an operational update. “During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, su.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended December 31, 2025. A press release det.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a public offering price of $4.10 per share. All of the shares in the offering are.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. In addition, TriSalus i.

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun “JJ” Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board exp.

TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).